Sandra A Hemkemeyer

Dr. Sandra A Hemkemeyer

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
RERobert Eckenstaler
Robert Eckenstaler
ARAnne Ripperger
Anne Ripperger
MHMichael Hauke
Michael Hauke
MPMarkus Petermann
Markus Petermann
SHSandra A Hemkemeyer
Sandra A Hemkemeyer
RBRalf Benndorf
Ralf Benndorf
Background: TP (thromboxane A 2 receptor) plays an eminent role in the pathophysiology of endothelial dysfunction and cardiovascular disease. Moreover, its expression is reported to increase in the intimal layer of blood vessels of cardiovascular high-risk individuals. Yet it is unknown, whether TP upregulation per se has the potential to affect the homeostasis of the vascular endothelium. Methods: We combined global transcriptome analysis, lipid mediator profiling, functional cell analyses, and in vivo angiogenesis assays to study the effects of endothelial TP overexpression or knockdown/knockout on the angiogenic capacity of endothelial cells in vitro and in vivo. Results: Here we report that endothelial TP expression induces COX-2 (cyclooxygenase-2) in a G i/o - and G q/11 -dependent manner, thereby promoting its own activation via the auto/paracrine release of TP agonists, such as PGH 2 (prostaglandin H 2 ) or prostaglandin F 2 but not TxA 2 (thromboxane A 2 ). TP overexpression induces endothelial cell tension and aberrant cell morphology, affects focal adhesion dynamics, and inhibits the angiogenic capacity of human endothelial cells in vitro and in vivo, whereas TP knockdown or endothelial-specific TP knockout exerts opposing effects. Consequently, this TP-dependent feedback loop is disrupted by pharmacological TP or COX-2 inhibition and by genetic reconstitution of PGH 2 -metabolizing prostacyclin synthase even in the absence of functional prostacyclin receptor expression. Conclusions: Our work uncovers a TP-driven COX-2–dependent feedback loop and important effector mechanisms that directly link TP upregulation to angiostatic TP signaling in endothelial cells. By these previously unrecognized mechanisms, pathological endothelial upregulation of the TP could directly foster endothelial dysfunction, microvascular rarefaction, and systemic hypertension even in the absence of exogenous sources of TP agonists.

24 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
CMClare Mills
Clare Mills
SHSandra A Hemkemeyer
Sandra A Hemkemeyer
ZAZerin Alimajstorovic
Zerin Alimajstorovic
CBChantelle Bowers
Chantelle Bowers
MEMalihe Eskandarpour
Malihe Eskandarpour
Maria Susana BaldaMaria Susana Balda
Maria Susana Balda
Inflammation and fibrosis are important components of diseases that contribute to the malfunction of epithelia and endothelia. The Rho guanine nucleotide exchange factor (GEF) GEF-H1/ARHGEF-2 is induced in disease and stimulates inflammatory and fibrotic processes, cell migration, and metastasis. Here, we have generated peptide inhibitors to block the function of GEF-H1. Inhibitors were designed using a structural in silico approach or by isolating an inhibitory sequence from the autoregulatory C-terminal domain. Candidate inhibitors were tested for their ability to block RhoA/GEF-H1 binding in vitro, and their potency and specificity in cell-based assays. Successful inhibitors were then evaluated in models of TGFβ-induced fibrosis, LPS-stimulated endothelial cell-cell junction disruption, and cell migration. Finally, the most potent inhibitor was successfully tested in an experimental retinal disease mouse model, in which it inhibited blood vessel leakage and ameliorated retinal inflammation when treatment was initiated after disease diagnosis. Thus, an antagonist that blocks GEF-H1 signaling effectively inhibits disease features in in vitro and in vivo disease models, demonstrating that GEF-H1 is an effective therapeutic target and establishing a new therapeutic approach.

18 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SHSandra A Hemkemeyer
Sandra A Hemkemeyer
SQStefania Quintiliani
Stefania Quintiliani
ASAndré Schaller
André Schaller
RMRaouf Madhkour
Raouf Madhkour
EEElena G Elchinova
Elena G Elchinova
MRMarina Rieder
Marina Rieder
Aims: Arrhythmogenic cardiomyopathy (ACM) is a genetic disease defined by arrhythmias and myocardial fibrosis with impaired cardiac function and increased risk of sudden cardiac death. Pathogenic variants are mostly identified in desmosomal genes such as desmoglein-2 (DSG2). We identified a novel disease phenotype in patients homozygous for the DSG2 variant c.523+2T>C (splice site of exon 5/intron 5), characterized by cardioembolic events in addition to classical ACM features. Here, we evaluate this new thromboembolic phenotype by comparing the clinical data to specific murine disease models. Methods and Results: We describe three unrelated patients presenting with an embolic event and/or left ventricular thrombus. Clinical evaluation revealed a shared right ventricular ACM phenotype characterized by arrhythmias, impaired function, and fibrotic remodeling. In addition, patients exhibited localized fibrotic changes of the left ventricular apex with formation of an aneurysm and predisposition to thrombus formation. Genetic analysis identified the DSG2 variant c.523+2T>C as a founder variant from the "Bernese Oberland". To elucidate the variant's functional impact, a mouse model deficient for Dsg2 exon 5 (Dsg2Δex5) was established and compared to a model carrying the adhesion-deficient Dsg2-W2A variant. Echocardiography, ECG, and histology in Dsg2Δex5 mice revealed similar disease patterns to patients and a loss of DSG2 expression. Importantly, these animals exhibited left apical fibrosis with aneurysm formation and left ventricular thrombus formation. In contrast, the Dsg2-W2A model presented with a biventricular ACM-phenotype but without left ventricular thrombi. Conclusions: We identified a novel ACM phenotype in patients homozygous for the DSG2 founder variant c.523+2T>C characterized by left ventricular apical fibrosis. Dsg2Δex5 mice recapitulate the patients' phenotype suggesting a causative link between left ventricular aneurysm due to DSG2 deficiency and thrombus formation with subsequent embolism. This highlights a novel pathological feature of ACM and the need for variant and phenotype-specific therapy.

11 November 2026 in Molecular Brain
Verified
Journal Article
Open access
PDF file
AEAmelie Eichler
Amelie Eichler
JBJosefine Biermann
Josefine Biermann
SHSandra A Hemkemeyer
Sandra A Hemkemeyer
JHJan Hegermann
Jan Hegermann
CSCamilla Schinner
Camilla Schinner
MLMaximilian Lenz
Maximilian Lenz
Heart failure is frequently accompanied by cognitive impairment, yet structural correlates in the brain remain incompletely defined. Here, we assessed whether chronic heart failure is associated with synaptic ultrastructural remodeling in the murine neocortex using a mouse model of arrhythmogenic cardiomyopathy caused by a point mutation in desmoglein-2 (Dsg2-W2A). Brains from aged adult homozygous Dsg2-W2A mice and age-matched wildtype controls were processed for transmission electron microscopy, and excitatory synapses in layer I of the prefrontal cortex were quantitatively assessed, with comparative analyses in the somatosensory cortex. In the prefrontal cortex, presynaptic terminal area and synaptic vesicle number were reduced in mutant mice, whereas postsynaptic measures were not altered. The prevalence of mitochondria and the spine apparatus within synapses was comparable between genotypes, suggesting no major loss of synapse-associated organelles. Finally, synaptic parameters in the prefrontal cortex did not show a systematic dependence on distance to local blood vessels. Together, these findings indicate moderate region- and compartment-specific synaptic ultrastructural alterations associated with Dsg2 cardiomyopathy and chronic heart failure, with predominant effects on presynaptic terminals.

19 December 2022
Verified
Book Chapter
Closed access
PDF file
SHSandra A Hemkemeyer
Sandra A Hemkemeyer
CCClaudia Carlantoni
Claudia Carlantoni
MFMaike Frye
Maike Frye